Treatment of hyponatraemia in patients with SIADH or CHF with intravenous conivaptan (YM087), a new combined vasopressin V1A/V2 receptor antagonist

被引：0
|
作者：
Abraham, W
Koren, M
Bichet, DG
Verbalis, JG
Klapholz, M
Selaru, P
Bakker-Arkema, RG
Rummel, SA
机构：
[1] Univ Cincinnati, Coll Med, Dept Cardiol, Cincinnati, OH USA
[2] Jacksonville Ctr Clin Res, Jacksonville, FL USA
[3] Hop Sacre Coeur, Montreal, PQ H4J 1C5, Canada
[4] Georgetown Univ, Med Ctr, Washington, DC 20007 USA
[5] Univ Med & Dent New Jersey, Newark, NJ 07103 USA
[6] Warner Lambert Co, Parke Davis Pharmaceut Res Div, Ann Arbor, MI USA
来源：
EUROPEAN HEART JOURNAL | 2000年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1848
引用
收藏
页码：345 / 345
页数：1
相关论文
共 50 条
  • [1] Pharmacotherapy for hyponatraemia in heart failure: effects of a new combined vasopressin V1A/V2 receptor antagonist, conivaptan (YM087) administered orally
    Abraham, W
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    Nelson, C
    Bakker-Arkema, RG
    EUROPEAN HEART JOURNAL, 2000, 21 : 345 - 345
  • [2] Hemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist in patients with advanced heart failure
    Udelson, JE
    Smith, WB
    Hendrix, GH
    Painchaud, CA
    Ghazzi, MM
    Thomas, I
    Ghali, JK
    Selaru, P
    Pressler, ML
    Konstam, MA
    CIRCULATION, 2000, 102 (18) : 593 - 593
  • [3] Haemodynamic effects of conivaptan hydrochloride (YM087, CI-1025) a combined vasopressin V1A and V2 receptor antagonist, in patients with advanced heart failure
    Udelson, J
    Smith, WB
    Hendrix, G
    Painchaud, C
    Ghazzi, MM
    Thomas, I
    Ghali, J
    Selaru, P
    Pressler, M
    Konstam, M
    EUROPEAN HEART JOURNAL, 2001, 22 : 394 - 394
  • [4] In vivo and in vitro characterisation of a nonpeptide vasopressin V1A and V2 receptor antagonist (YM087) in the rat
    Risvanis, J
    Naitoh, M
    Johnston, CI
    Burrell, LM
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 381 (01) : 23 - 30
  • [5] Pharmacotherapy for hyponatremia in heart failure:: Effects of a new dual V1A/V2 vasopressin antagonist YM087
    Abraham, WT
    Suresh, DP
    Wagoner, LE
    Haas, GJ
    McCord, J
    Rydzinski, S
    Nelson, CB
    Bakker-Arkema, RG
    CIRCULATION, 1999, 100 (18) : 299 - 299
  • [6] Cardiovascular and renal effects of conivaptan hydrochloride (YM087), a vasopressin V1A and V2 receptor antagonist, in dogs with pacing-induced congestive heart failure
    Yatsu, T
    Tomura, Y
    Tahara, A
    Wada, K
    Kusayama, T
    Tsukada, J
    Tokioka, T
    Uchida, W
    Inagaki, O
    Iizumi, Y
    Tanaka, A
    Honda, K
    EUROPEAN JOURNAL OF PHARMACOLOGY, 1999, 376 (03) : 239 - 246
  • [7] Conivaptan:: A dual receptor vasopressin V1a/V2 antagonist
    Ali, Farhan
    Raufi, M. Adnan
    Washington, Barbara
    Ghali, Jalal K.
    CARDIOVASCULAR DRUG REVIEWS, 2007, 25 (03): : 261 - 279
  • [8] Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects
    Burnier, M
    Fricker, AF
    Hayoz, D
    Nussberger, J
    Brunner, HR
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 55 (09) : 633 - 637
  • [9] Pharmacokinetic and pharmacodynamic effects of YM087, a combined V1/V2 vasopressin receptor antagonist in normal subjects
    M. Burnier
    A. F. Fricker
    D. Hayoz
    J. Nussberger
    H. R. Brunner
    European Journal of Clinical Pharmacology, 1999, 55 : 633 - 637
  • [10] Conivaptan (CI-1025, YM087), a combined vasopressin V1A/V2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients
    Smith, WB
    Russell, S
    Ghali, JK
    Painchaud, CA
    Selaru, P
    Ghazzi, MM
    Konstam, MA
    Udelson, JE
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 37 (02) : 172A - 173A
12345